Johns Hopkins Center for Psychedelic & Consciousness Research

Dr. Sandeep Nayak presented findings from our clinical trial of psilocybin for PTSD at the Interdisciplinary Conference on Psychedelic Research (ICPR) 2026 in the Netherlands. Stay tuned for full results published soon!

Interested in experiencing psychedelics under professional supervision? We are seeking healthy adults between the ages 21-65 to participate in a new clinical trial looking at the effects of psilocybin and its interaction with other medications. Apply at https://jhmi.co1.qualtrics.com/jfe/form/SV_24EiE5zrBib6vNY?Source=FBPost_626.

Phone: 443-927-3282
Email: [email protected]
Website: https://hopkinspsychedelic.org/prismatic

CPCR Assistant Professor, Dr. Brandon Weiss, interviews with CNBC regarding the executive order on accelerated psychedelic research. Weiss cautions that there are different risks associated with each psychedelic compound: “My biggest concern would be that FDA standards are relaxed for politically motivated reasons,” he said. “It’s not clear that that is the case, but what’s required is a lot more scientific research and a very objective interpretation of the risks and benefits.”

Why Trump reversed course to fast-track psychedelic drugs for mental healthcare President Donald Trump is trying to fast-track research into psychedelics as treatments, creating new opportunities and risks.

JHU PhD student Katherine Cheung and PhD Candidate Caleigh Propes, with CPCR Associate Professor Dr. David Yaden, evaluated comparison sets on the price of Oregon’s psilocybin services. As the first state in the U.S. to legalize psilocybin access and a key reference point on how other states might design psychedelic policy, this exploration helps ground discussion on Oregon’s prices in more careful analysis for future debates.

https://bioethicstoday.org/blog/evaluating-the-price-of-oregons-psilocybin-services-finding-the-right-comparison/ #

Blog - Evaluating the Price of Oregon’s Psilocybin Services: Finding the Right Comparison - Bioethics Today Oregon’s psilocybin services are often described as quite expensive in both media coverage and academic discussions. However, when making this claim, we

Drs. Fred Barrett and David Yaden have received a 2026 Johns Hopkins Nexus Award alongside fellow JHU scientists, educators, bioethicists, and economists. Their convening will bring together leaders across clinical, ethical, economic, and public health fields to advance critical conversations around the future of psychedelic policy. As the science matures, so must the policy conversations around it, and we are grateful to Johns Hopkins for supporting that work.

Johns Hopkins announces funding for Washington, D.C.-based projects and research The Nexus Awards Program supports a diverse range of programming, research, and teaching activities at the Hopkins Bloomberg Center

Congratulations to Kristy Arthur on an outstanding showing at the Collaborative Perspectives on Addiction Annual Meeting! Kristy presented as part of a symposium on psilocybin for substance use disorders — including how people in recovery can become certified to support others on their journey — and her poster was selected for the 2026 Poster Research Excellence Award in Clinical Translational Research. Well deserved! 🎉

Join us Wednesday for the Psychedelic Archives Project Guest Speaker Series!
🎤Dr. Timo Schmidt
🗓 May 25, 2026 | ⏰ 4:30 PM EDT
🎟 Free to attend — sign up at the link below and in our bio!👇

https://jhubluejays.zoom.us/j/92622903856

This Memorial Day, we honor those who gave everything in service to this country and we hold space for those still carrying invisible wounds.

If you or a loved one is a Veteran struggling with posttraumatic stress, we do have an open clinical trial that may be of interest.

PAMVET Trial — Johns Hopkins Center for Psychedelic and Consciousness Resarch Are You a Military Veteran Suffering from PTSD?We are seeking military Veterans with Posttraumatic Stress Disorder (PTSD) to participate in a research study looking at the effects of psilocybin and M**A, two substances often called "psychedelics". Separately, both substances have shown some early si...

Check out this thoughtful interview with Dr. Bit Yaden and Josh Hardman at Psychedelic Alpha, discussing a collaborative educational project between Johns Hopkins, NYU, Penn, and Yale. The project focuses on training resident psychiatrists on the most important aspects of prescribing psychedelic medicines, including safety, equity and inclusion, and understanding the unique profiles and clinical uses of various psychedelic substances.
https://psychedelicalpha.com/news/bit-yaden-on-preparing-the-next-generation-of-psychiatrists-for-a-psychedelic-future/

"Psychiatry has so many tools, and psychedelics are going to be one of them. We should legitimise that, make space for it, talk about it. But we also do patients a disservice if we act like this is the only thing that could ever help them. Psychiatry has much more to offer than just psychedelic medicine." - Bit Yaden

Read the full conversation on our website: https://psychedelicalpha.com/news/bit-yaden-on-preparing-the-next-generation-of-psychiatrists-for-a-psychedelic-future/

CPCR Medical Director, Dr. Sandeep Nayak, will be speaking at the Interdisciplinary Conference on Psychedelic Research in the Netherlands on June 4-6!